Purchase Order 75N91019P00505

<p>The National Cancer Institute issued a purchase order to Illumina, Inc. for $17,675.00 on July 31, 2019, with ultimate completion on July 31, 2020. The order covers a maintenance agreement for DNA and RNA sequencing equipment, with work performed in San Diego, California. Pricing is firm fixed price with no set-aside applied.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. for $26,357.76 on June 29, 2017, with an ultimate completion date of June 30, 2018. Work is performed in San Diego, California. The order covers sequencing reagents, consumables, or related biotechnology products and services. No set-aside category applied to this procurement.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. for $20,987.00 on August 31, 2017, with final completion scheduled for March 19, 2018. Performance takes place in Bethesda, Maryland. The order covers sequencing instruments, reagents, consumables, or bioinformatics software—Illumina's core product portfolio for federal genomic research applications. Pricing is firm fixed price with no set-aside applied.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. for $4,066.13 on December 4, 2017, with a completion date of January 31, 2018. The order covers a maintenance agreement for Illumina sequencing equipment. Work is performed in San Diego, California. The purchase order carries firm fixed price terms and no set-aside designation.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. for $9,600.01 on March 5, 2010, with an ultimate completion date of April 4, 2010. The order carries firm fixed price terms and no set-aside designation. Place of performance is San Diego, California. The procurement covers sequencing instruments, reagents, consumables, or bioinformatics software aligned with Illumina's core product portfolio in DNA and RNA sequencing technologies.</p>

<p>The National Cancer Institute issued a delivery order to Illumina, Inc. on July 26, 2017, with a ceiling value of $22,188.47 for genetic sequencing equipment and consumables, with ultimate completion by August 28, 2017.</p> <p>Place of performance is Bethesda, MD. The order is firm fixed price with no set-aside designation. Illumina specializes in DNA and RNA sequencing instruments, reagents, and bioinformatics software supporting genomic research across federal agencies.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. for $12,130.80, with an award date of June 15, 2020 and ultimate completion date of June 20, 2021. Work is performed in San Diego, California. The order is for service agreement items on a firm fixed price basis with no set-aside applied.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. for $16,085.00 on April 30, 2019, with a completion date of April 30, 2020. The order covers a maintenance agreement for sequencing equipment, performed in San Diego, California. No set-aside applied to this acquisition.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. for $12,875.00 on July 25, 2018, with an ultimate completion date of July 31, 2019. No set-aside was used. Work is performed at Bethesda, Maryland. The order is priced on a firm fixed price basis and procures sequencing instruments, reagents, consumables, or bioinformatics software aligned with Illumina's product portfolio in support of cancer research operations.</p>

<p>The National Cancer Institute issued a $13,402.80 delivery order to Illumina, Inc. on May 20, 2019, for NSQ 500/550 high-output sequencing kits (150 units) on a firm fixed-price basis.</p> <p>Place of performance is San Diego, CA 92122. The order was due for completion on June 19, 2019. No set-aside was applied.</p>